FDA Approves HAE Drug Berinert For Pediatric Use

Post Date: 
19 July 2016

The FDA has approved Berinert [C1 Esterase Inhibitor (Human)], to be used in pediatric patients to treat Hereditary Angioedema (HAE) attacks. This expansion means Berinert is the only approved HAE treatment available to patients under 12 years of age.

 Clinical studies have shown that intervention with Berinert at the onset of an HAE attack brings significantly faster relief to a patient and reduces the severity of the attack.
 Berinert is a plasma-derived C1 Esterase Inhibitor (Human) indicated for the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) in adult and pediatric patients.

Read More here